Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

Haemonetics will release fiscal Q2 2027 results at 6:00 a.m. ET on November 5, 2026, followed by an investor and analyst conference call at 8:00 a.m. ET. The announcement contains no financial results, guidance, or operational updates, making it a routine earnings-date notification.

Analysis

This is a scheduling notice rather than an information-bearing operating update; it creates no standalone fundamental catalyst and should not alter positioning. The relevant setup is the pre-earnings expectation curve: HAE’s mixed portfolio makes the November report sensitive to whether higher-margin plasma/collection consumables can offset procedure-volume, hospital-capital, and integration-related variability in MedSurg.

Over the next 1-3 months, monitor sell-side estimate revisions, plasma-collection-center utilization commentary from operators, and any change in management’s full-year organic-growth or margin framework. A positive report needs evidence that growth is converting to operating leverage rather than being absorbed by commercial investment, manufacturing costs, or acquisition/integration spending; absent that, a premium medtech multiple is vulnerable to compression even on an in-line revenue print.

The non-obvious risk is that apheresis demand strength can conceal customer concentration and purchasing-cycle volatility among large plasma collectors. Conversely, if plasma operators accelerate capacity additions while interventional procedure demand remains resilient, HAE has an earnings-mix upside that broad medtech proxies such as IHI may not fully capture. There is no actionable directional signal from this release alone; the event is best treated as a dated catalyst for an estimates-and-positioning review.

Key Decisions for Investors

• Maintain neutral HAE exposure until pre-call checks establish whether consensus revenue, gross-margin, and EPS estimates have moved materially; do not buy the calendar announcement.
• Set an alert for November 5 results: consider a long HAE only if organic growth and adjusted operating-margin guidance are raised, with particular focus on recurring disposables/consumables growth. Falsify on a guide-down or margin deterioration despite revenue growth.
• For existing HAE longs, reduce event risk if the stock materially outperforms IHI into earnings without corresponding upward EPS revisions; that divergence raises the probability of post-print multiple compression on merely in-line results.
• Watch plasma-collection operator utilization and center-opening trends through October. Confirmed acceleration supports a 6-18 month consumables-growth thesis; weaker utilization would argue against adding HAE even if near-term quarterly results meet expectations.